Compass Therapeutics, Inc. — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
On November 19, 2026, Compass Therapeutics received notice of failure to satisfy continued listing standards (Item 3.01). The filing does not specify which exchange issued the notice, the specific listing rule violated, or remediation timeline. This is a material corporate governance event for the $277M market-cap company.
Why this rating
Delisting notice threatens market access and investor liquidity; existential risk for small-cap biotech. Specific violation details absent, but event itself is trajectory-altering.
Extracted items
Price action (we called it negative)
before filing · preread $0.69 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.